AQST News and Press, Aquestive Therapeutics Inc. From 09/29/21

SAINT LAURENT, Quebec, Sept. 29, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and ben...

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the managem...

Provides access to $30 million in capital contingent on FDA approval and U.S. market access for Libervant WARREN, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated pr...

WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...

Aquestive Therapeutics, Inc. (AQST) Q2 2021 Earnings Conference Call August 4, 2021, 8:00 am ET Company Participants Stephanie Carrington - IR Keith Kendall - President & CEO Ernie Toth - CFO Ken Marshall - SVP, CCO Dan Barber - COO Conference Call Participants Evan Seigerman - BMO Capita...

Aquestive Therapeutics (NASDAQ:AQST) gains 7% after-hours after reporting consensus beating results for Q2 ended June 30, 2021. Total revenues fell 29.2% Y/Y to $15.3M, but ahead of analyst forecast of $9.48M. Sympazan net revenue surged 47% compared to prior year. Shipment volume g...

Libervant™ NDA resubmission accepted, PDUFA goal date of December 23, 2021 On track to report top-line data from Phase 1 study for AQST-109 epinephrine sublingual film in second half 2021 Increases full year revenue guidance Hosts conference call at 8:00 a.m. ET ...

The rapid spread of the COVID-19 Delta variant is fostering renewed investor interest in the biotech industry. Also, with the increasing demand for treatments for other critical diseases, the industry is expected to continue on a growth trajectory. So, we think it could be wise to bet on biot...

WARREN, N.J., July 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...

Are These Penny Stocks Worth It After The Stock Market Crash? With the Dow down by over 900 points, investors were searching for penny stocks that could still have growth potential. But, to understand how to make money with penny stocks today, we have to understand why the market dr...